Among colleagues who trained under Rowley:
- Michelle Le Beau, PhD, director of the University of Chicago Medicine Comprehensive Cancer Center, is a leading authority in hematologic malignancies and her groundbreaking research led to the discovery that there are several distinct genetic subtypes of therapy-related leukemias. Her current research focus is on therapy-related acute myeloid leukemia.
- Dr. Funmi Olopade is an expert in cancer risk assessment and individualized treatment for the most aggressive forms of breast cancer, having developed novel management strategies based on an understanding of the altered genes in individual patients. She stresses comprehensive risk reducing strategies and prevention in high-risk populations, as well as earlier detection through advanced imaging technologies.
- Dr. Megan McNerney, PhD, used big data to help her discover that gene CUX1, which acts as a tumor suppressor, is frequently inactivated in acute myeloid leukemia.
For more: http://sciencelife.uchospitals.edu/2015/03/30/the-emperor-of-all-maladies-documentary-thrusts-cancer-into-the-national-spotlight/